Candel Therapeutics (NASDAQ:CADL) Upgraded to Hold at Zacks Investment Research

Retrieved on: 2022-06-02 22:32:35

Tags for this article:

Click the tags to see associated articles and topics

Candel Therapeutics (NASDAQ:CADL) Upgraded to Hold at Zacks Investment Research. View article details on hiswai:

Excerpt

Millennium Management LLC now owns 13,106 shares of the company's stock valued at $102,000 after acquiring an additional 2,460 shares during the last ...

Article found on: www.etfdailynews.com

View Original Article